SCHEMBL4893602

SCHEMBL4893602

C=C1C2CC3CC(C2)CC1C3

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382039 0.78
SCHEMBL17633027 0.76
SCHEMBL2815843 0.69 TSHR (0.38) TSHRKDM4EALDH1A1LMNA
SCHEMBL12765788 0.67 TSHR (0.33) TSHR
SCHEMBL14162153 0.67
Ethylene SCHEMBL1617394 0.67 TSHR (0.37) TSHRKDM4E
Adamantane SCHEMBL28908472 0.66 CYP2C9 (0.40) TSHRLMNA
SCHEMBL13018767 0.66
Adamantane SCHEMBL12761 0.66 CYP2C9 (0.46) TSHRLMNA
Adamantane SCHEMBL29707714 0.66 CYP2C9 (0.46) TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217484-B Naphthalimide derivative based on methylene adamantane modification as well as preparation method and application thereof 苏州大学 2024-04-05 CN claimed
CN-116217484-A Naphthalimide derivative based on methylene adamantane modification as well as preparation method and application thereof 苏州大学 2023-06-06 CN claimed
CN-110770282-A Curable silicone composition, and application and use thereof 莫门蒂夫性能材料股份有限公司 2020-02-07 CN claimed
US-10287400-B2 Curable silicone composition and applications and uses thereof MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2019-05-14 US claimed
CN-109312077-A Curable silicon composition and its application and use 莫门蒂夫性能材料股份有限公司 2019-02-05 CN claimed
US-20170298188-A1 CURABLE SILICONE COMPOSITION AND APPLICATIONS AND USES THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. 2017-10-19 US claimed
US-20080051597-A1 Process for Producing 2-Methyladamantan-2-Yl (Meth)Acrylate and 2-Methyladamantan-2-Yl (Meth)Acrylate MITSUBISHI CHEMICAL CORPORATION (JP) 2008-02-28 US claimed
US-7148363-B2 Process for preparing acrylate compound TOSOH CORPORATION (JP) 2006-12-12 US claimed
US-6833462-B2 Esterification to get cyclic acrylate compounds; used as raw material for functional polymers, pharmaceuticals, pesticides, semiconductor lithography TOSOH CORPORATION (JP) 2004-12-21 US claimed
EP-1230227-B1 BENZOXA-AND BENZOTHIAZOLYL SULFAMATES AND THEIR USE AS STEROID SULFATASE INHIBITORS NOVARTIS AG (CH) 2004-06-23 EP claimed
US-6716865-B1 SUBSTITUTED AT THE 2 POSITION; A SULFAMATE BOUND VIA OXYGEN TO THE PHENYL PART OF THE RING STRUCTURE; SULFAMOYLATION; STEROID SULFATASE INHIBITOR, ACNE NOVARTIS AG (CH) 2004-04-06 US claimed
US-20030139613-A1 Process for preparing acrylate compound TOSOH CORPORATION 2003-07-24 US claimed
EP-1230227-A1 BENZOXA-AND BENZOTHIAZOLYL SULFAMATES AND THEIR USE AS STEROID SULFATASE INHIBITORS Novartis AG (CH) 2002-08-14 EP claimed
WO-2001036398-A1 BENZOXA- AND BENZTHIAZOLES NOVARTIS AG (CH) 2001-05-25 WO claimed
EP-3515892-B1 COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2026-04-15 EP disclosed
WO-2025043152-A1 METHODS OF DEALKENYLATIVE AMINATION AND AZIDATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-27 WO disclosed
US-12122730-B2 Methods of carbon-carbon bond fragmentation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-10-22 US disclosed
EP-0554244-A1 ADAMANTANE POLYMERIC COMPOSITIONS MOBIL OIL CORPORATION (US) 1993-08-11 EP disclosed
WO-1992007018-A1 ADAMANTANE POLYMERIC COMPOSITIONS MOBIL OIL CORPORATION (US) 1992-04-30 WO disclosed
US-5053434-A Diamondoid polymeric compositions MOBIL OIL CORPORATION (US) 1991-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298188-A1 CURABLE SILICONE COMPOSITION AND APPLICATIONS AND USES THEREOF VCL, CCNI, SMCHD1 TSHR 4542/4885KDM4E 2206/4885ALDH1A1 1443/4885
US-20030139613-A1 Process for preparing acrylate compound AFF1, AFF4, RER1 TSHR 994/4885KDM4E 1056/4885ALDH1A1 241/4885
US-10287400-B2 Curable silicone composition and applications and uses thereof VCL, CCNI, SMCHD1 TSHR 4542/4885KDM4E 2206/4885ALDH1A1 1443/4885
US-12122730-B2 Methods of carbon-carbon bond fragmentation CYCS, COX6C, COXFA4L2 TSHR 4604/4885KDM4E 4206/4885ALDH1A1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.